VASA — Heart Failure with Preserved Ejection Fraction
Heart Failure with Preserved Ejection Fraction (HFpEF)
Protocol: VS-041-102
About this study
A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Sponsor: Vasa Therapeutics. CRO: Medpace. Principal Investigator: Dr. Pedro Martinez-Clark. ClinicalTrials.gov lists NCT07219511 as active, not recruiting (update posted 23 Oct 2026). This study is not on the public active list.
Sponsor: Vasa Therapeutics, Inc. · Principal Investigator: Pedro Martinez-Clark, MD, FACC
Key eligibility
- Adults with HFpEF (LVEF ≥ 50%)
- Stable on guideline-directed medical therapy
- Meeting protocol biomarker criteria
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.